Get started

Vaccine

*THE TRADING REGIME #BITCOIN ANALYSIS - OCT 2020 TO JAN 2021*Hello Traders We’ve decided to add #BTCUSD to our watchlist for the end of the year. Cryptocurrency is still fairly new to the market and lack regulation We normally don’t trade it due to several factors however, here’s the complete analysis and price points marked out. It’s currently showing #bulls in charge But keep in mind the bearish engulfing also present from $13k Touch. Crypto trading tips: Be safe and take low risk(WHAT YOUR COMFORTABLE LOSING—-SCRATCH THE 1-2% theory 😂) ask me why in comments! Be patient and disciplined in your approach((TRADE YOUR PLAN/RULE BASED APPROACH) Don’t follow the “HERD”(HYPE/HERESAY) Always protect your capital(stop loss) Always only risk what can afford to lose. The Trading Regime COINBASE:BTCUSD
B
by EvaultFinancialGroup
1
SPY TESTING ATH? Will Earnings Push Us Over? Market Breakdown“There are enough trends out there, established by Covid, that just say, ‘Get long,’” CNBC’s Jim Cramer said on Monday. The “Mad Money” host said that strength in the tech sector is likely to support the market, regardless of the election outcome. “I think there’s a genuine belief that it doesn’t matter who wins. It doesn’t matter about stimulus,” said Cramer. - $SPY confirmed it's bullish trend on the daily after it broke and closed above $333. I talked about this setup on Monday, 9/28/20. Few things to watch as we move forward: RGEN - Regeneron CEO cautions Trump’s results are ‘a case of one,’ and coronavirus drug needs more testing President Trumps Health - White House physician says Trump has tested negative for Covid, is no longer infectious. SPY levels - After the gap up we saw back on Sep 28 (first signal of bullish trend). Easy Loot going into earnings season
AMEX:SPY
by DotcomJack
{SWC}—— Dpharma, Breakout DTLDpharma had broken out short term downtrend line, presented Piercing candlestick pattern and continued closed it share price at MA20 last Friday. More volume needed to push up the price. MA5 and MA10 consolidation Momentum Chips (red chips) show a positive signal. Do also note that this counter will be affected by vaccine news. Bias: Long Resistance: 3.35, 3.50 Support: 3.15, 3 (use MA 10 as support) If you find this idea helpful, kindly leave us a like and comment!
MYX:DPHARMALong
by ShareWorldConsulting
SPHealth 2 Week Comparisons (Oct 7-20 2020)SPHealth - Growth Analysis & Comparison - Cindicator Poll Submission (October 7th - 20th 2020) I've been looking through my Cindicator questions, making forecasts and watching markets as new polls pop up. Here's a comparison chart for 5 major S&P health companies and my rankings forecast. (Descending order from most growth to least) United Health Group Inc (UNH) Abbott Labs (ABT) Johnson & Johnson (JNJ) Pfizer Inc. (PFE) Merck & Co. (MRK) This forecast will be explicitly graded by total growth % comparisons of opening prices on October 7th to closing prices on October 20th across the 5 aforementioned companies. As of right now before 10-9-20 daily market open, the percentage growth is as follows: UNH +1.9% PFE +1.87% JNJ +1.56% ABT +1.1% MRK +0.54% When looking at a specific metric within the already completed duration since I submitted my forecast, overall recent growth is: UNH +2.82% PFE +2.66% JNJ +2.24% MRK +2.22% ABT +1.62% 10-9-20 Forecast Adjustments: Now that I have seen the last 2 days play out, I'm starting to notice a couple things about my forecast and actual live value. I'm confident that United Health will still outperform, but this outlook could change if any major market sell off occurs before the 20th. Pfizer looks like it could be a strong runner up, and I may have flubbed my original forecast by ranking it 4th in growth. Johnson & Johnson is performing approximately as expected. Merck and Abbott Labs could be tricky to pinpoint exactly without some further research and analysis but, I'm guessing that Abbott may come in 4th place if everything settles after any quick rallies that should happen. If a light pump in Merck occurs over the 19th-20th, then there could be a small chance it outperforms Abbott for 4th but it feels like an unlikely scenario. After these deliberations, I've decided my forecast doesn't need much adjusting other than to swap the placement of Pfizer and Abbott. My updated forecast is as follows: United Health Group Inc (UNH) Pfizer Inc. (PFE) Johnson & Johnson (JNJ) Abbott Labs (ABT) Merck & Co. (MRK) One thing to note is that I believe TradingView is not calculating its percentage scale correctly, its placing the 0% Y axis at the close value of the first candle used to calculate growth. So this graph is really just more for me to check my own work by hand, as the percentages on the left will not accurately portray what is actually being graded by Cindicator. I'll check back in after the 20th to see how this turned out! Thanks for tuning in :) Disclaimer, I am not responsible for any losses incurred while attempting to use my data, I hope this can prove to be some sort of learning tool for some and give insight as to how I personally come up with my own numbers. Take into full consideration this could be a completely bad forecast. Cheers
NYSE:UNH
by Hambooger
MRNA HOLD BULLISHI am not swinging this one, even though it is tempting. I recently sold NVAX at 15% profit, and due to strong correlation with MRNA I was considering selling my MRNA as well, in which case I would have made 14% right now. However, I decided to hold because of 2 reasons : 1) AstraZeneca just took a major hit (if you don't know about it, catch up on the news). This takes out a bit of competition and investor fund distribution might come this way 2) MRNA shows a strong uptrend with good momentum, and that is mainly why I will HOLD it for longer term. Hit like if you found this helpful and interesting. Thanks, E
NASDAQ:MRNA
by BlockTechEv
9
MRNA - THE CEO THAT SOLD - SHARE YOUR FEEDBACKPLEASE READ THE ENTIRE POST, IT MIGHT JUST SAVE YOU A SOUR INVESTMENT I have been following MRNA for about a month now, and something interesting has happened that not many people know about. On 4 September, news came out that the CMO, the President AND the CEO have sold large if not all of their holdings.* Now the company says that this is no reason to panic. (sounds like what we were told about corona in December...) On the trading platform I use, I have also gotten a notification about insiders selling. This is a built in strategy used along with others to determine the market consensus of the stock (buy, strong buy, hold etc) We can all probably agree that when head management sell most of their holdings, and not 1 person but 3 senior members, it is generally not a good sign. Now here is where I'd like your feedback - The large selling off their stocks hasn't been reflecting in the market. In fact, MRNA has been on one long bull run with minor short term bearish chart patterns. Why would it be that the sell off doesn't reflect in the market? I personally sold my stock immediately after I saw a report on this from Gurufinder, later confirmed by more mainstream news and other platforms. My opinion is that The company has to portray that they believe their stocks are going all the way up which in this case, selling off massive holdings at the peak tells me that they are taking their profit. Compare this to PFE (Pfizer), whos director INCREASED his holdings. Now that speaks of confidence in the company, right? * INFO FROM MY TRADING PLATFORM CEO, SOLD $1,293,810, DATE 18.09.20 PRESIDENT, SOLD $1,228,468, DATE 15.09.20 CMO, SOLD $1,255,321, DATE 15.09.20 Please share your constructive and respectful feedback, and thank you ! Hit like if you found this interesting, Ev
NASDAQ:MRNA
by BlockTechEv
7
Is MRNA revealing major upside opportunity? BULL or BEAR? Today we're looking at MRNA aka Moderna, the darling biotech that might be the savior of us all should they produce an mRNA vaccine that could be more easily produced and distributed at scale than a traditional vaccine candidate. Reading into this story I've been intrigued, especially with the nice patterns forming in this chart with an easy to identify Impulse wave and a correction pattern currently forming. Unfortunately, this is always the riskier proposition and we must consider our Bull and Bear cases objectively so that we have a plan. As you'll see, we recently bounced off the 0.5 fib retracement from the all-time high of $95 all the way back to $53. Looks like a healthy bounce off that level. But we should almost always expect it. There is nothing to get excited about until we see a more convincing bounce with volume. While I love the long term pattern being set up in this chart with that hopeful bull target of $136.99, there's a lot of work to make up and resistance to overcome before we get anywhere close. The declining volume is something to watch out for. If you zoom in you'll see the upward channel off the bounce paired with the declining volume. This would indicate that short term we'll retest the low, and if we're lucky we can get a buying opportunity off that low and off the 0.618 at $43.50. Set your ladders appropriately and always calculate your stop loss according to risk preference fo % loss below average calculated cost. If you plan your buy levels and amount in advance you can easily calculate the average buy price and then subtract 20% for example to reach a reasonable stop loss which shields you from setting a stop loss too high and missing the following run, or setting it too low and losing more than you are willing to. Meanwhile, looking at the long term trend, we'll have some trading potential on the stock, but need to look for some volatility within the current correction pattern. Given the sharp increase and resulting decrease, one can assume we might see similar moves again in the future, though there's nothing to indicate exactly when at the moment until we see a better channel or a convincing wedge reveal itself. The longer-term trend bodes well for your everyday investor who's willing to take some loss for a very large potential gain. Should Moderna create their mRNA based vaccine in time and be successful with distribution, the value of this company would quickly skyrocket. I'm willing to bet on an optimistic future and I'm definitely keeping an eye on this opportunity with the buy ladders I've mentioned indicated. What's your Bull and Bear case on Moderna? How would you play this in the short and long term?
NASDAQ:MRNA
by Shadowfigure
2
NVAX UP 13%NVAX is HOT right now. Earlier yesterday I expected a pullback, but there is no way of telling when the buy craze will end. What I'm monitoring from the chart: Momentum, to indicate a possible trend reversal - for now the momentum is still HOT RSI, also to monitor momentum and buy power - right now the buyers are in firm control Bollinger Bands, to monitor the volatility and overbought / oversold area - we have been running overbought for days So at this point, NVAX is going incredibly strong but I am keeping an eye out for a possible sell off or minor correction to enter again with a lower position. Hit like if you found this helpful Thanks, E
NASDAQ:NVAX
by BlockTechEv
1
$VBIV 10 Day MA Reversal and Curl on the Daily10 day MA reversal and curl. Today's candle is just now passing though the 10 day MA but still presents an opportunity for the bears so if the bulls keep the price up we may be able to break this and that should give confirmation of a bullish reversal. Inverted hammer appearing after the series of red candles is indicative that a reversal is about to occur. However, since the next candle did not open above the previous day's close, this indicates the bears may still take control. Further confirmation would be needed to take the trade long.Depending on risk tolerance 2.84-3.02 stop/loss 4.56 target, if it blows past that... woo hoo!
V
by VelvetBarbie
1
Small account play with potential upcoming COVID catalystVaccine play: “Four vaccine candidates developed from VXRT's proprietary VAAST platform were assessed in mouse models and elicited a strong immune response.” (finance.yahoo.com) Potential upcoming catalyst of a Phase 1 trial As of last week, down 73% since the yearly high, has begun to reverse. Very oversold on SlowStoch and has been for nearly a month Below 100day SMA, only slightly above 200day SMA Fib targets above, can use 0 fib below for stop loss.
NASDAQ:VXRTLong
by SpinTrades
$C6L Swing Trade AnalysisIn this post, I will be going in detail with regards to my view of $C6L from a technical perspective. As of the time that I am writing this post, $C6L is trading at $3.560. I am fully aware that, right now, it may not be the best time to invest in the airline industry due to the uncertainties that surround it. We do not know when a vaccine will be developed, we do not know when a newly developed vaccine will be available for the masses, we do not know whether $C6L will be able to survive the crisis, we do not know whether there will be a new wave of COVID-19 infection, we do not know when international travel will resume, we do not know how long it will take before travelers overcome the fear of getting infected and start traveling in the future. I can write a whole list of reasons why investing in C6L, or any airline company right now is too early. As such, currently, I am bearish on $C6L as long as international traveling is not widely allowed and COVID-19 vaccines are not available for the masses yet. However, despite being aware of all of the above, I still have small positions in $C6L which averaged up to a cost price of $3.652. This is a very long term position that I entered with money that I am comfortable with losing. The reason I did so was that after doing my own due diligence, I strongly believe that $C6L will be able to pull through the COVID-19 crisis because of its strong fundamentals and the financial backing that Singapore provides to the company. Singapore will not let $C6L go under. Of course, this is a very speculative play on my part, so I hope that before you enter into a position into $C6L, think twice, and ensure that you are able to stomach the potential downside that any airline industry investment can bring during such an uncertain period. Technical Analysis I believed that I have broken down the technical aspect of $CCL's chart quite clearly in the candlestick chart above, but just to emphasis on a few things: 1. I strongly believe that if the support zone that I've marked with a star is breached + if everything else remains status quo, or possibly, gets worse, we will definitely revisit $3.200. If the situation remains the same or worse after the retest of $3.200, we will undoubtedly breach it and enter the $3.000 zone and beyond. As such, I believe that right now, we are at a very crucial level from a technical perspective. 2. This is similar to the first point, but I want to emphasize that the upside potential for $C6L is bleak. All, if not most of the movements towards the upside will be extremely dependent on the news releases. Furthermore, even if there are news releases that positively impact $C6L, the upward movement will not be sustainable unless the news is related to confirmation of vaccines being successfully developed and distributed, or if it is regarding a widespread resume of air travel. 3. I believe that currently, should COVID-19 eases and the demand for air travel rises, the fair value of $C6L will be somewhere between $5.500 to $6.000. So, if prices of $C6L push up, my profit target will be right around there. 4. Lastly, I believe that an optimal entry price will be whichever price that $C6L is at when news of vaccines is made available in Singapore (or when there is a news release with a similar impact scale-wise). However, there's also the saying that "Time in the market beats timing the market". As such, you can still enter a small position at the current market price and slowly average down/up; but that is provided that you are able to stomach the possible downside that has still yet to come. Disclaimer I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment, or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. I will not and cannot be held liable for any actions you take as a result of anything you read here. Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise. If this post has helped you out in making your investment/trading decision, do it give it a like, and follow for more updates regarding this ticker symbol!
SGX:C6LLong
by UnknownUnicorn6361804
BioNTech Stock Will Soar With Its First-Mover Vaccine AdvantageNASDAQ:BNTX a German company and its american partner NYSE:PFE will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in. Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table! The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s. Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization The advantage of their trial is that it is large, involving more than 30,000 participants. The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization. Why BioNTechs Vaccine Looks Like a Winner With Pfizer in the back FDA and President Donald Trump are likely to move quickly. According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies. With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients. BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat This combined with the huge buying volume and market shifts will grant momentum for bigger goals. Just think about what ccould happen when they get kinda a monopol situation going for them. Thank you for take the time and reading this and as always stay storng in those shaky times! Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
4
The Coronavirus Vaccine: Best Trading Tips for GoldGold has not been nearly as affected by the risk-on frenzy as bonds were. In fact, it has been maintaining a range from 1924 to 1964. These are both technical levels. There are some Fibonacci levels in between so watch for support or resistance at these. The fact that gold is maintaining a $40 range which is quite narrow for this product, suggests a breakout may follow soon. This narrow range is not likely to last, so keep your eye on the upper and lower bounds of the channel for a possible breakout either way. The Kovach OBV is solidly bearish, but this could just be because we are testing the lower bound of the range right now. The level 1925 may provide some support here very soon
COMEX:GC1!Long
by quantguy